FFAR2 and metabolic dysfunction-associated steatotic liver disease: Acetate serves as both an energy substrate and signaling molecule, with experimental studies demonstrating its capacity to activate hepatic free fatty acid receptor 2 (FFAR2), thereby improving insulin sensitivity and attenuating lipid accumulation in MASLD models (Aoki et al., 2021).